Endocrine Abstracts

Somatostatin receptors (sstr1–5) and dopamine receptor 2 (D2DR) are expressed and co-localized in several endocrine tumors including pituitary adenomas that express both D2DR and various subtypes of somatostatin receptors, depending on the original cell type. Treatment of pituitary adenomas using somatostatin or dopamine analogs targets only one receptor (octreotide/lanreotide mainly sst2, cabergoline D2DR). Association of octreotide and cabergoline showed limited additiv...

Lost to follow-up (LTFU) is a frequent problem in chronic diseases not evaluated yet in acromegaly despite the long-term need of medical treatment and complications survey in this disease.Objectives: Evaluation of the prevalence of LTFU patients in a multi-center cohort, characteristics of defaulters and description of their evolution after they have been searched and found.Méthods: Observational multicentric (25 centers study...

Introduction: CD is a rare disease. Our aim was to describe demographic and clinical characteristics together with initial management of patients with CD.Patients and methods: A retrospective analysis of 437 CD patients diagnosed between 1996 and 2009, followed in 5 tertiary centers (Bordeaux, Grenoble, Lyon, Marseille, Paris) was performed in the frame of the national program for rare diseases.Results: 347 (80%) were women. Mean a...

Introduction: Somavert is a GH receptor blocker, which inhibits hepatic production of IGF1. While it has been approved for the treatment of acromegaly since 2003 there are few data regarding its effects in everyday clinical practice.Methods/design: ACROSTUDY is an open-label, international, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of Somavert.Results: As of Dece...